Testing and treatment of arterial graft thrombosis.
The in vivo technique of Sauvage et al for determining prosthetic arterial graft thrombogenicity was employed in the sheep carotid model using 4 mm commercial expanded polytetrafluoroethylene (Gore-Tex) grafts. Expanded polytetrafluoroethylene was found to be thrombogenic at 4 hours of low flow in this model. At 24 hours all of these grafts were totally occluded at low flow rates. Intravenous use of ibuprofen (Motrin), a thromboxane inhibitor, in this model markedly reduced occlusion and thrombogenicity at 4 and 24 hours. All grafts were patent at 24 hours when ibuprofen was used.
D000818:Animals; D001158:Arteries / Q000637:transplantation; D001241:Aspirin / Q000627:therapeutic use; D001807:Blood Vessel Prosthesis; D003251:Constriction, Pathologic / Q000188:drug therapy; D004195:Disease Models, Animal; D006085:Graft Survival; D006965:Hyperplasia / Q000188:drug therapy; D007052:Ibuprofen / Q000627:therapeutic use*; D008297:Male; D011138:Polytetrafluoroethylene / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy*; D012756:Sheep; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014182:Transplantation, Autologous
D011138:Polytetrafluoroethylene; D001241:Aspirin; D007052:Ibuprofen